Global Health Limited share price
NSE: MEDANTA · ISIN INE474Q01031
Key numbers
- Market cap
- ₹ 40,185 Cr
- Current price
- ₹ 1,495.40
- 52-week high / low
- ₹ 1,544 / 956
- Stock P/E
- 72.5
- Book value
- ₹ 147.5
- Dividend yield
- 0.03%
- ROCE
- 17.1%
- ROE
- 15.1%
- Debt to equity
- 0.30
- Sales growth (3 yrs)
- 17.2%
- Profit growth (3 yrs)
- 19.5%
- 1-year return
- 12.5%
About Global Health Limited
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, lab and pathology, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinions, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup services. In addition, the company is involved in trading pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Operating profit | 227 | 231 | 217 | 244 | 287 |
| Net profit | 159 | 158 | 95 | 144 | 159 |
| EPS (₹) | 5.92 | 5.89 | 3.54 | 5.36 | 5.91 |
Concall summary (2026-08-05)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Profit after tax was INR1,573 million compared to INR1,590 million in Q1 FY26.
- More importantly, the EBITDA loss declined sharply from INR236 million in Q4 FY26 to only INR49 million in Q1 FY27.
Growth & demand
- Inpatient volumes increased by 28% year -on-year, while outpatient volumes grew by 34%, reflecting sustained demand across our specialties and the continued scale -up of our new facilities.
- International patient revenue witnessed a growth of 23% year -on-year to INR782 million, reflecting strong growth despite current geopolitical tensions.
Margins & costs
- EBITDA, excluding Noida, witnessed a growth of 24% year-on-year to INR3,201 million, with margins improving to 25.8%, highlighting the continued strength of our core operating portfolio.
- Reported EBITDA, including Noida stood at INR3,153 million, registering a healthy 23% year- on-year growth with EBITDA margins of 23.8%.
Capex & expansion
- Occupied bed days for the quarter increased by 21% with network occupancy remaining h ealthy at 63% on expanded bed capacity.
- Overall, the Cluster 2 hospitals witnessed a 50% increase in inpatient volumes, while occupied bed days increased by 44%, re flecting continued capacity expansion across the hospitals.
Balance sheet & cash
- If you see our overall cash flow has been strong over previous year, and we see continuously happening that way only.
- And we are not seeing any decline in our cash flow generation.
Peers in Medical Care Facilities
- Apollo Hospitals Enterprise Limited
- Max Healthcare Institute Limited
- Manipal Health Enterprises Limited
- Aster DM Quality Care Limited
- Fortis Healthcare Limited
- Narayana Hrudayalaya Limited
- Krishna Institute of Medical Sciences Limited
- Rainbow Children's Medicare Limited
- Park Medi World Limited
- Yatharth Hospital & Trauma Care Services Limited
Data for information only, not investment advice. Prices end of day.